FDA Approves Adjuvant Belzutifan Plus Pembrolizumab in High-Risk ccRCC After Nephrectomy: LITESPARK-022 Data

KEY FINDINGS

• Approval: On 12 June 2026 the FDA approved belzutifan (Welireg) with pembrolizumab (Keytruda) as adjuvant treatment in ccRCC patients at intermediate-high or high risk of recurrence after nephrectomy.
• LITESPARK-022 phase 3: In 1,841 patients, the combination arm achieved a 28% reduction in the risk of recurrence or death for DFS (HR 0.72; 95% CI 0.59-0.87; p=0.0003).
• Overall survival: Not yet mature and has not reached statistical significance (HR 0.78; p=0.1220).
• Safety: The rate of grade ≥3 adverse events was markedly higher in the combination arm (52.1% versus 30.2%), requiring close monitoring particularly for anaemia and hypoxia.

Study Design and Background

The clear cell subtype of renal cell carcinoma (ccRCC) carries a significant recurrence rate in patients at intermediate-high or high risk after nephrectomy. Adjuvant pembrolizumab monotherapy had previously become the standard of care in this population with the KEYNOTE-564 trial; however, the need for combination strategies to reduce recurrence risk further persisted.

LITESPARK-022 (NCT05239728) randomized 1,841 ccRCC patients 1:1 who had undergone nephrectomy within 12 weeks of surgical resection and were at intermediate-high or high risk of recurrence, or who had no evidence of disease after resection of metastases (M1 NED). Patients were assigned either to up to 9 cycles of 400 mg intravenous pembrolizumab (every 6 weeks) plus 120 mg oral belzutifan (a HIF-2α inhibitor) daily for up to 54 weeks, or to pembrolizumab plus placebo. The primary endpoint was disease-free survival (DFS).

Key Results

Subgroup analysis: While the benefit of adding belzutifan appeared most pronounced in intermediate-high risk patients, no additional benefit over the pembrolizumab-alone arm was observed in the high-risk and M1 NED subgroups. The overall survival (OS) analysis remains immature at the interim stage with 87 events (approximately 29% of the events required for the final analysis).

Implications for Clinical Practice

1. A candidate for a new adjuvant standard

LITESPARK-022 is important as the first phase 3 adjuvant combination trial to show a significant disease-free survival advantage against an active immunotherapy comparator (pembrolizumab monotherapy). These results make belzutifan plus pembrolizumab a candidate for a new adjuvant standard in intermediate-high and high risk ccRCC patients after nephrectomy.

2. Toxicity and close monitoring

The marked increase in the rate of grade ≥3 adverse events (52.1% versus 30.2%), particularly in terms of the risk of anaemia and hypoxia, underlines the importance of patient selection and close laboratory monitoring throughout treatment.

3. Individualisation by risk stratification

The pronounced benefit observed in the intermediate-high risk group, alongside the limited additional contribution in the high-risk and M1 NED subgroups, indicates that the treatment decision should be individualised according to risk stratification.

Conclusion

The FDA approval of 12 June 2026 represents an important milestone in post-surgical adjuvant treatment of renal cell carcinoma. The LITESPARK-022 data show that combining HIF-2α inhibition with immunotherapy can deliver a concrete clinical benefit in reducing recurrence risk. That said, the increased toxicity profile and immature overall survival data highlight the importance of ongoing follow-up studies to determine which patient subgroups derive the most favourable risk-benefit balance from this combination.

References

• FDA approves belzutifan with pembrolizumab for adjuvant treatment of renal cell carcinoma. U.S. Food and Drug Administration. 12 June 2026. - fda.gov
• Adjuvant Belzutifan in Combination With Pembrolizumab Receives FDA Approval in Renal Cell Carcinoma. ASCO Post. - ascopost.com
• LITESPARK-022 DFS data make case for belzutifan/pembrolizumab as new standard in ccRCC. Urology Times. - urologytimes.com
• ASCO GU 2026: Adjuvant Pembrolizumab + Belzutifan versus Pembrolizumab for Clear Cell RCC - The Randomized Phase 3 LITESPARK-022 Study. UroToday. - urotoday.com
• FDA Approval Positions Belzutifan Plus Pembrolizumab as a New Adjuvant Standard in ccRCC. OncLive. - onclive.com
• FDA Approves Belzutifan with Pembrolizumab for Adjuvant Treatment of Renal Cell Carcinoma. American Society of Clinical Oncology (ASCO). - asco.org